GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO)

INR 2852.45

(-3.62%)

Operating Income Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual operating income in 2023 was 13.6 Billion INR , up 12.01% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly operating income in 2024 Q2 was 3.04 Billion INR , up 42.37% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported an annual operating income of 7.55 Billion INR in 2022, up 7.22% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported an annual operating income of 7.04 Billion INR in 2021, up 33.67% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly operating income of 2.14 Billion INR for 2024 Q1, down -10.47% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly operating income of 2.39 Billion INR for 2023 Q4, up 4.41% from previous quarter.

Annual Operating Income Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual Operating Income of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	Operating Income	Operating Income Growth
2023	13.6 Billion INR	12.01%
2022	7.55 Billion INR	7.22%
2021	7.04 Billion INR	33.67%
2020	5.26 Billion INR	-11.9%
2019	5.97 Billion INR	5.44%
2018	5.67 Billion INR	16.33%
2017	4.87 Billion INR	20.43%
2016	4.04 Billion INR	-15.07%
2015	4.76 Billion INR	-2.44%
2014	4.88 Billion INR	-28.72%
2013	6.85 Billion INR	-29.28%
2012	9.69 Billion INR	4.33%
2011	9.28 Billion INR	4.46%
2010	8.89 Billion INR	17.98%
2009	7.53 Billion INR	31.59%
2008	5.72 Billion INR	18.79%
2007	4.82 Billion INR	26.05%
2006	3.82 Billion INR	30.57%
2005	2.92 Billion INR	-18.81%
2004	3.6 Billion INR	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	3.04 Billion INR	42.37%
2024 Q1	2.14 Billion INR	-10.47%
2023 Q4	2.39 Billion INR	4.41%
2023 Q2	2.71 Billion INR	112.81%
2023 Q3	2.29 Billion INR	-15.59%
2023 FY	8.45 Billion INR	12.01%
2023 Q1	1.27 Billion INR	-16.41%
2022 FY	7.55 Billion INR	7.22%
2022 Q1	1.33 Billion INR	-16.74%
2022 Q2	2.4 Billion INR	80.74%
2022 Q3	2.12 Billion INR	-11.76%
2022 Q4	1.52 Billion INR	-28.14%
2021 Q3	1.79 Billion INR	-30.5%
2021 Q2	2.58 Billion INR	93.28%
2021 Q4	1.59 Billion INR	-11.15%
2021 FY	7.04 Billion INR	33.67%
2021 Q1	1.33 Billion INR	-12.47%
2020 Q3	1.86 Billion INR	-3.06%
2020 Q2	1.91 Billion INR	27.77%
2020 Q1	1.5 Billion INR	166.49%
2020 FY	5.26 Billion INR	-11.9%
2020 Q4	1.53 Billion INR	-17.75%
2019 Q4	563.7 Million INR	-54.01%
2019 FY	5.97 Billion INR	5.44%
2019 Q3	1.22 Billion INR	-34.53%
2019 Q2	1.87 Billion INR	5.73%
2019 Q1	1.77 Billion INR	-11.75%
2018 Q3	1.41 Billion INR	-15.93%
2018 FY	5.67 Billion INR	16.33%
2018 Q4	2 Billion INR	41.58%
2018 Q2	1.68 Billion INR	18.45%
2018 Q1	1.42 Billion INR	0.0%
2017 Q1	259.1 Million INR	0.0%
2017 FY	4.87 Billion INR	20.43%
2016 FY	4.04 Billion INR	-15.07%
2015 FY	4.76 Billion INR	-2.44%
2014 FY	4.88 Billion INR	-28.72%
2013 FY	6.85 Billion INR	-29.28%
2012 FY	9.69 Billion INR	4.33%
2011 FY	9.28 Billion INR	4.46%
2010 FY	8.89 Billion INR	17.98%
2009 FY	7.53 Billion INR	31.59%
2008 FY	5.72 Billion INR	18.79%
2007 FY	4.82 Billion INR	26.05%
2006 FY	3.82 Billion INR	30.57%
2005 FY	2.92 Billion INR	-18.81%
2004 FY	3.6 Billion INR	0.0%

Peer Operating Income Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	Operating Income	Operating Income Difference
Abbott India Limited	13.79 Billion INR	1.392%
Cipla Limited	105.7 Billion INR	87.133%
Gland Pharma Limited	9.9 Billion INR	-37.292%
Kopran Limited	615.26 Million INR	-2110.762%
Marksans Pharma Limited	7.79 Billion INR	-74.573%
NGL Fine-Chem Limited	416.27 Million INR	-3167.589%
Pfizer Limited	9.61 Billion INR	-41.515%
Sanofi India Limited	7.79 Billion INR	-74.407%
SMS Pharmaceuticals Limited	833.64 Million INR	-1531.635%